ClinicalTrials.gg

Program

DDY391

A development code.

In Novartis's pipeline, VAV1-directed MGD. Its studies are mostly in Arthritis, Psoriatic · Sjogren's Syndrome, led by Novartis.

Furthest: phase 2, since Jul 27, 20263 company-led studies, 3 open or runningNext primary completion: Dec 13, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis33 open or runningphase 2since Jul 27, 2026Jul 27, 2026Dec 13, 2028phase 2 · NCT07801495
  • Named in Novartis’s own pipeline as DDY391, phase 2, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 27, 2026First study: phase 2 study in Sjogren's SyndromeFirst studyNCT07737743 · 344 planned · United States, Australia, Canada and more
  2. Aug 31, 2026Phase 2 study in Arthritis, PsoriaticNCT07801495 · 220 planned · United States
  3. Nov 2, 2026Phase 2 study in Arthritis, PsoriaticNCT07923773 · 88 planned

Ahead

  1. Dec 13, 2028Primary completion: phase 2 study in Arthritis, PsoriaticNCT07801495
  2. Feb 19, 2029Primary completion: phase 2 study in Sjogren's SyndromeNCT07737743
  3. Dec 12, 2029Primary completion: phase 2 study in Arthritis, PsoriaticNCT07923773

TargetBeta

“VAV1-directed MGD”the company's pipeline, read by Claude · source

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07923773Arthritis, Psoriatic2Not yet recruitingDec 12, 202988
NCT07801495Arthritis, Psoriatic · United States2RecruitingDec 13, 2028220
NCT07737743Sjogren's Syndrome · United States, Australia, Canada and more2RecruitingFeb 19, 2029344

How it is read

Names in the registry

  • “DDY391”, 3 entries

Codes read as this program: DDY391.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.